A double blind randomised controlled trial comparing standard dose of iron supplementation for pregnant women with two screen-and-treat approaches using hepcidin as a biomarker for ready and safe to receive iron
Amat Bah, Rita Wegmuller, Carla Cerami, Lindsay Kendall, Sant-Rayn Pasricha, Sophie E Moore, Andrew M Prentice
BMC Pregnancy and Childbirth | BMC | Published : 2016
Awarded by Medical Research Council
The trial will not be possible without the funding provided by the Bill and Melinda Gates Foundation to the MRC-ING. The trial is also supported by the UK MRC and the UK Department for International Development (DFID) under the MRC/DFID Concordant agreement. We appreciate the valuable contribution of Momodou W. Jallow and Ebrima Ceesay for analysing the blood samples for the determination of the hepcidin cut-off point used in this trial.